Barcelona, Spain, March 21st, 2024
Peptomyc S.L., a clinical stage company specialized in the development of protein therapeutics targeting the MYC oncoprotein for cancer treatment, today announced the appointment of Dr. Selwyn Ho, MB, BS, to its Board of Directors.
Giacomo Di Nepi, Chairman of Peptomyc, says: “We are delighted to have Selwyn joining us. His impressive track record in the Healthcare sector, together with his experience in different executive and Board roles at some of the most prestigious Pharma and Biotech companies worldwide, represent a huge new asset for our company. I am confident that Selwyn will significantly contribute to the success of our project, help further expanding our strategic options and collaborations, and bring a new and valuable point of view to the table.”
Laura Soucek, CEO of Peptomyc, adds: “This is an extraordinary addition to the Board and we are all excited to start working with Selwyn. I am confident that, with his outstanding experience in the sector, he will bring valuable and strategic insights, and contribute to further shaping our corporate vision, governance, and long-term goals”.
“I am excited to join Peptomyc’s Board, a company with first-in-class leadership of therapeutics designed to target the MYC oncogene ” says Selwyn Ho. “. I believe Peptomyc’s first MYC inhibitor, OMO-103, has the potential to deliver significant benefit to patients across multiple cancers, and its recent and promising early clinical data indicate that this is a key moment to join the company. I am very much looking forward to working closely with the rest of the Board, as well as with Dr. Soucek and the Executive Team to accelerate the further progress of the company.”.
Dr. Ho is a highly experienced Pharma and Biotech executive and qualified medical physician, with a track record of success in corporate development and strategy, financing, commercialization, product development and general management in the Biotech and Pharmaceutical organisations in Europe, the U.S. and International Markets. Dr. Ho currently serves as Chief Executive Officer of Medigene AG, (FRA: MDG1), an early-stage immuno-oncology company focused on the development of T cell receptor (T cell) therapies for solid tumors. In addition, he is an Executive in Residence at New Rhein Healthcare Investors, an investment firm applying a private equity business model to venture capital investing, and a Non-Executive Director at Immodulon Therapeutics Ltd, a private, late-stage clinical company developing a novel, broad spectrum immunomodulator.
Prior, to Medigene, Dr. Ho served as Chief Business Officer at Connect Biopharma (NASDAQ: CNTB), a global, clinical-stage biopharmaceutical company focused on developing innovative therapies that treat chronic inflammatory diseases. Prior to Connect, Dr. Ho held leadership positions at Dermira (acquired by Lilly in 2020), UCB, Allergan (Acquired by Abbvie in 2020), Novartis and AstraZeneca.
About Peptomyc
Peptomyc (www.peptomyc.com) is a spin-off from VHIO –the Vall d’Hebron Institute of Oncology –and ICREA –the Catalan Institute of Research and Advanced Studies -, founded in December 2014 in Barcelona, Spain. The company is focused on the development ofinnovative cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment and based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years. It is the first company to have successfully completed a Phase 1 clinical trial with a direct MYC inhibitor.